The C3i Center, a leading Canadian organization in cell and gene therapy, has announced a significant addition to its management team. The company revealed that Bobby Boursiquot has been appointed as its new Vice President of Commercialization, effective November 10, 2025.
A Strategic Hire for Market Growth
Boursiquot brings over two decades of experience in scientific innovation and commercial growth within the biopharmaceutical sector. His primary mandate at C3i Center will be to lead initiatives designed to accelerate the transfer of groundbreaking cell and gene therapy discoveries from the laboratory to the marketplace.
Yvan Côté, President and CEO of C3i Center, expressed strong confidence in the new appointment. He highlighted Boursiquot's unique blend of scientific rigor and commercial foresight, stating his arrival will strengthen the center's core mission to translate research into real-world treatments that improve patient outcomes.
Boursiquot's Proven Track Record
Prior to joining C3i Center, Boursiquot served as Director of Business Development and Partnerships at CERASP (Center for Expertise and Applied Research in Pharmaceutical Sciences). In this role, he successfully established numerous collaborations with universities, biotech start-ups, and funding organizations.
His previous experience includes a tenure as Director of Business Development at Neopharm Labs Inc., where he led a multidisciplinary team and achieved remarkable results, including doubling the company's revenue over a five-year period and maintaining a customer retention rate exceeding 90%.
Boursiquot's career began in analytical chemistry and quality assurance, with successive management roles at companies like BioEnvelop. This foundation gives him a deep understanding of the entire product lifecycle, from initial discovery to the commercialization of compliant therapies.
Bridging the Innovation Gap
In his statement, Bobby Boursiquot addressed a critical challenge in the medical field. He noted that the gap between a laboratory discovery and a life-saving therapy is where many innovations fail. He expressed his enthusiasm for joining C3i Center, which is specifically designed to bridge that gap.
"I am delighted to join the team and focus on establishing the strong industrial partnerships needed to bring these essential treatments to market and make them available to patients faster than ever before," Boursiquot said.
His academic credentials include a Bachelor of Science in Chemistry from Concordia University, an MBA from UQAM, and a certificate in Business Management from HEC Montréal.
About C3i Center
C3i Center is a full-service provider and a commercial GMP CDMO (Contract Development and Manufacturing Organization). With 15 years of experience and a 99% success rate in over 300 clinical productions, the company specializes in transforming research into tangible cell and gene therapies. Its services encompass everything from process development to commercialization, supported by a state-of-the-art GMP facility and a comprehensive in-house analytical center.
